American Academy of Periodontology Journal of Periodontology Online Welcome Guest
Sign in | Register
 
Abstract
August 2005, Vol. 76, No. 8, Pages 1259-1264 , DOI 10.1902/jop.2005.76.8.1259
(doi:10.1902/jop.2005.76.8.1259)

Cyclosporin-Induced Gingival Overgrowth: A Clinical–Epidemiological Evaluation of 121 Italian Renal Transplant Recipients

Paolo Vescovi

Oral Pathology and Medicine Unit, Section of Odontostomatology, Department of ENTDental-Ophthalmological and Cervico-Facial Sciences, University of Parma, Parma, Italy.

Dr. Marco Meleti

Oral Pathology and Medicine Unit, Section of Odontostomatology, Department of ENTDental-Ophthalmological and Cervico-Facial Sciences, University of Parma, Parma, Italy.

Maddalena Manfredi

Oral Pathology and Medicine Unit, Section of Odontostomatology, Department of ENTDental-Ophthalmological and Cervico-Facial Sciences, University of Parma, Parma, Italy.

Elisabetta Merigo

Oral Pathology and Medicine Unit, Section of Odontostomatology, Department of ENTDental-Ophthalmological and Cervico-Facial Sciences, University of Parma, Parma, Italy.

Giuseppe Pedrazzi

Department of Public Health, University of Parma, Parma, Italy.

Background: Although other immunosuppressive agents have been recently introduced (e.g., tacrolimus), it has been calculated that in the next decade about 1 million people will still be taking cyclosporin (CsA). The association between gingival overgrowth (GO) and the use of CsA is still not clear. In the present study we evaluated the prevalence and the degree of GO in a group of Italian renal transplant patients and the possible relationship between gingival lesions and demographic, oral, systemic, and pharmacological variables.

Methods: One hundred twenty-one renal transplant recipients receiving immunosuppressive therapy with CsA were evaluated in this study. Patients were classified in two groups. In the first (screening group), we included all those patients referred by the Parma University Renal Transplant Center for a general oral checkup, with no specific indications for GO. The second group (non-screening group) included all those patients who specifically had been referred to the Oral Pathology and Oral Medicine Unit because of GO. We considered the following variables: gender, daily CsA dose, duration of immunosuppressive treatment, CsA plasma concentration, concomitant use of another immunosuppressive agent (azathioprine), use of other GO inducers (calcium channel blockers, anti-epileptic drugs), oral hygiene scores, and other drugs taken at the time of oral examination.

Results: Fisher's exact test and chi square test demonstrated that in the screening group, duration of immunosuppressive treatment and oral hygiene scores were associated both with the prevalence and the high GO scores (P 1 DIT <0.0001; P 2 DIT = 0.0023; P 1 hyg = 0.0084; P 2 hyg = 0.0068). In the screening group, concomitant use of CsA and azathioprine is related to a low development degree of GO (P = 0.0088). In the non-screening group, we found a significant association between poor oral hygiene and high degree of GO (P = 0.0349).

Conclusion: In addition to a probable genetic predisposition, duration of immunosuppressive treatment and oral hygiene status are the most important variables related to development and degree of GO during the use of CsA in this study. J Periodontol 2005;76: 1259-1264.

KEYWORDS: Cyclosporin A/adverse effects , dental plaque index , gingival hyperplasia/etiology , immunosuppressive agents/therapeutic use , Italians , periodontal diseases/etiology , renal transplantation/adverse effects

Cited by

, , , , , , , . (2009) Oral Disease Burden and Utilization of Dental Care Patterns Among Pediatric Solid Organ Transplant Recipients. Journal of Public Health Dentistry 69:1, 48-55
Online publication date: 1-Feb-2009.
CrossRef
, , , , . (2008) Gingival Status of Brazilian Renal Transplant Recipients Under Sirolimus-Based Regimens. Journal of Periodontology 79:11, 2060-2068
Online publication date: 1-Nov-2008.
Abstract | Full Text | PDF (489 KB) | PDF Plus (563 KB) 
, , , , , , . (2008) Gingival Overgrowth in Dogs Associated with Clinically Relevant Cyclosporine Blood Levels: Observations in a Canine Renal Transplantation Model. Veterinary Surgery 37:3, 247-253
Online publication date: 1-May-2008.
CrossRef
, , . (2008) Gingival Enlargement Among Renal Transplant Recipients in the Era of New-Generation Immunosuppressants. Journal of Periodontology 79:3, 453-460
Online publication date: 1-Mar-2008.
Abstract | Full Text | PDF (481 KB) | PDF Plus (549 KB) 
, , , , , . (2007) Demographic, Pharmacologic, and Periodontal Variables for Gingival Overgrowth in Subjects Medicated With Cyclosporin in the Absence of Calcium Channel Blockers. Journal of Periodontology 78:2, 254-261
Online publication date: 1-Feb-2007.
Abstract | Full Text | PDF (290 KB) | PDF Plus (322 KB) 
, , , , , , , . (2007) Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: Quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes. Nephrology 12:6, 607
CrossRef
, , , , . (2006) Prevalence, Severity, and Risk Variables Associated With Gingival Overgrowth in Renal Transplant Subjects Treated Under Tacrolimus or Cyclosporin Regimens. Journal of Periodontology 77:6, 969-975
Online publication date: 1-Jun-2006.
Abstract | Full Text | PDF (154 KB) | PDF Plus (214 KB) 
PDF (125.474 KB) PDF Plus (237.895 KB)
 

Previous Article | Next Article
View/Print PDF (125 KB)
View PDF Plus (238 KB)
Add to favorites
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Paolo Vescovi
Dr. Marco Meleti
Maddalena Manfredi
Elisabetta Merigo
Giuseppe Pedrazzi
Keywords:
Cyclosporin A/adverse effects
dental plaque index
gingival hyperplasia/etiology
immunosuppressive agents/therapeutic use
Italians
periodontal diseases/etiology
renal transplantation/adverse effects

© 2009 American Academy of Periodontology. All rights reserved.
Disclaimers apply | Privacy commitment | Contact AAP
Technology Partner - Atypon Systems, Inc.